FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES) - Business Wire

FDA Approves Nucala as the First and Only Biologic Treatment for Hypereosinophilic Syndrome (HES)  Business Wire